Literature DB >> 23584249

A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Yvonne Perrie1, Elisabeth Kastner, Randip Kaur, Alexander Wilkinson, Andrew J Ingham.   

Abstract

A range of particulate delivery systems have been considered as vaccine adjuvants. Of these systems, liposomes offer a range of advantages including versatility and flexibility in design format and their ability to incorporate a range of immunomodulators and antigens. Here we briefly outline research, from within our laboratories, which focused on the systematic evaluation of cationic liposomes as vaccines adjuvants. Our aim was to identify physicochemical characteristics that correlate with vaccine efficacy, with particular consideration of the interlink between depot-forming action and immune responses. A variety of parameters were investigated and over a range of studies we have confirmed that cationic liposomes, based on dimethyldioctadecylammonium bromide and trehalose 6,6'-dibehenate formed a depot at the injection site, which stimulates recruitment of antigen presenting cells to the injection site and promotes strong humoral and cell-mediated immune responses. Physicochemical factors which promote a strong vaccine depot include the combination of a high cationic charge and electrostatic binding of the antigen to the liposome system and the use of lipids with high transition temperatures, which form rigid bilayer vesicles. Reduction in vesicle size of cationic vesicles did not promote enhanced drainage from the injection site. However, reducing the cationic nature through substitution of the cationic lipid for a neutral lipid, or by masking of the charge using PEGylation, resulted in a reduced depot formation and reduced Th1-type immune responses, while Th2-type responses were less influenced. These studies confirm that the physicochemical characteristics of particulate-based adjuvants play a key role in the modulation of immune responses.

Entities:  

Keywords:  Liposomes; adjuvants; depot formation; dimethyldioctadecylammonium; formulation design; sub-unit antigens; vaccines

Mesh:

Substances:

Year:  2013        PMID: 23584249      PMCID: PMC3901835          DOI: 10.4161/hv.24694

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  48 in total

1.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.

Authors:  Ida Rosenkrands; Else Marie Agger; Anja W Olsen; Karen S Korsholm; Claire Swetman Andersen; Klaus T Jensen; Peter Andersen
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Liposomes: an overview of manufacturing techniques.

Authors:  M Reza Mozafari
Journal:  Cell Mol Biol Lett       Date:  2005       Impact factor: 5.787

4.  Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products.

Authors:  Afzal R Mohammed; Vincent W Bramwell; Allan G A Coombes; Yvonne Perrie
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

5.  Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.

Authors:  Jesper Davidsen; Ida Rosenkrands; Dennis Christensen; Anil Vangala; Daniel Kirby; Yvonne Perrie; Else Marie Agger; Peter Andersen
Journal:  Biochim Biophys Acta       Date:  2005-11-14

6.  A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.

Authors:  Anil Vangala; Daniel Kirby; Ida Rosenkrands; Else Marie Agger; Peter Andersen; Yvonne Perrie
Journal:  J Pharm Pharmacol       Date:  2006-06       Impact factor: 3.765

7.  Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens.

Authors:  C Klinguer; A Beck; P De-Lys; M C Bussat; A Blaecke; F Derouet; J Y Bonnefoy; T N Nguyen; N Corvaïa; D Velin
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

8.  Preparation and characterization of cationic microspheres for gene delivery.

Authors:  E Esposito; S Sebben; R Cortesi; E Menegatti; C Nastruzzi
Journal:  Int J Pharm       Date:  1999-10-28       Impact factor: 5.875

9.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition.

Authors:  Camilla Foged; Carmen Arigita; Anne Sundblad; Wim Jiskoot; Gert Storm; Sven Frokjaer
Journal:  Vaccine       Date:  2004-05-07       Impact factor: 3.641

View more
  5 in total

Review 1.  Recent Advances and Future Perspectives in Polymer-Based Nanovaccines.

Authors:  Natassa Pippa; Maria Gazouli; Stergios Pispas
Journal:  Vaccines (Basel)       Date:  2021-05-26

2.  Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.

Authors:  Christophe Barnier-Quer; Abdelrahman Elsharkawy; Stefan Romeijn; Alexander Kros; Wim Jiskoot
Journal:  Pharmaceutics       Date:  2013-07-25       Impact factor: 6.321

3.  Application of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System.

Authors:  Raj K S Badhan; Swapnil Khadke; Yvonne Perrie
Journal:  Pharmaceutics       Date:  2017-12-07       Impact factor: 6.321

4.  Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.

Authors:  Sameer Joshi; Atul A Chaudhari; Vida Dennis; Daniel J Kirby; Yvonne Perrie; Shree Ram Singh
Journal:  Bioengineering (Basel)       Date:  2018-05-09

5.  The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes.

Authors:  Seo Ri Wui; Ara Ko; Ji In Ryu; Eojin Sim; Soo Jeong Lim; Shin Ae Park; Kwang Sung Kim; Ha Kim; Hyewon Youn; Na Gyong Lee
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.